drugset
drugset / Trial / NCT04465266

A Phase 1 PK Study of Tolperisone in Healthy Subjects

NCT04465266 ↗

Phase 1 Completed 27 enrolled Neurana Pharmaceuticals, Inc.
RandomizedCrossoverSingle-blindOther

Summary

This is a randomized, single-blind, single and multiple dose crossover subjects in healthy adult subjects

Timeline

Start
2020-07-28
Primary completion
2020-08-21
Completion
2021-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Tolperisone Small molecule 50 mg —
Subject Tolperisone Small molecule 100 mg —
Subject Tolperisone Small molecule 200 mg —

Indications

No indication recorded.